Evidence map›Paper›PMID 25116894›Full record

ReviewBiotechnology advances2014

Three-dimensional in vitro tumor models for cancer research and drug evaluation.

Xian Xu, Mary C Farach-Carson, Xinqiao Jia

Abstract readReview
In one paragraph

Review in Biotechnology advances, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 195 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
195citing papers in PubMed, 2 pooled it
20.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

195 citing papers in PubMed, 2 syntheses or guidelines pooled it, 460 citations in OpenAlex.

  1. Models of Oral Epithelial Dysplasia: A Systematic Review and Temporal Analysis.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2026
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

135 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Xian XuDepartment of Materials Science and Engineering, University of Delaware, Newark, DE 19716, USA.
Mary C Farach-CarsonDepartments of Biochemistry and Cell Biology and Bioengineering, Rice University, Houston, TX 77251, USA; Center for Translational Cancer Research, University of Delaware, Newark, DE 19716, USA.
Xinqiao JiaDepartment of Materials Science and Engineering, University of Delaware, Newark, DE 19716, USA; Center for Translational Cancer Research, University of Delaware, Newark, DE 19716, USA; Biomedical Engineering Program, University of Delaware, Newark, DE 19716, USA. Electronic address: xjia@udel.edu.
University of Delaware · US

Funding

Predictive Modeling & Optimal Control Framework for Model-Based Epidemic Response in DelawareP20GM103446 · NIGMS · UNIVERSITY OF DELAWARE · PI Anjana Narayan Bhat · 2012 to 2026
$67.2M
Prostate Cancer Bone Metastasis: Biology and TargetingP01CA098912 · NCI · EMORY UNIVERSITY · PI ZAYZAFOON, MAJD · 2003 to 2019
$24.0M
VALGUS BRACING FOR MEDIAL LAXITY IN PATIENTS WITH OSTEOARTHRITISP20RR016458 · NCRR · UNIVERSITY OF DELAWARE · PI RUDOLPH, KATHERINE S · 2002 to 2011
$18.9M
Functional Assembly of Salivary Cells to Relieve XerostomiaR01DE022969 · NIDCR · RICE UNIVERSITY · PI FARACH-CARSON, MARY C, JIA, XINQIAO · 2012 to 2015
$2.5M
NCI NIH HHS P01 CA098912NCRR NIH HHS P20 RR016458NIDCR NIH HHS R01 DE022969NIGMS NIH HHS P20 GM103446
6 · The paper itself

Abstract

Cancer occurs when cells acquire genomic instability and inflammation, produce abnormal levels of epigenetic factors/proteins and tumor suppressors, reprogram the energy metabolism and evade immune destruction, leading to the disruption of cell cycle/normal growth. An early event in carcinogenesis is loss of polarity and detachment from the natural basement membrane, allowing cells to form distinct three-dimensional (3D) structures that interact with each other and with the surrounding microenvironment. Although valuable information has been accumulated from traditional in vitro studies in which cells are grown on flat and hard plastic surfaces (2D culture), this culture condition does not reflect the essential features of tumor tissues. Further, fundamental understanding of cancer metastasis cannot be obtained readily from 2D studies because they lack the complex and dynamic cell-cell communications and cell-matrix interactions that occur during cancer metastasis. These shortcomings, along with lack of spatial depth and cell connectivity, limit the applicability of 2D cultures to accurate testing of pharmacologically active compounds, free or sequestered in nanoparticles. To recapitulate features of native tumor microenvironments, various biomimetic 3D tumor models have been developed to incorporate cancer and stromal cells, relevant matrix components, and biochemical and biophysical cues, into one spatially and temporally integrated system. In this article, we review recent advances in creating 3D tumor models employing tissue engineering principles. We then evaluate the utilities of these novel models for the testing of anticancer drugs and their delivery systems. We highlight the profound differences in responses from 3D in vitro tumors and conventional monolayer cultures. Overall, strategic integration of biological principles and engineering approaches will both improve understanding of tumor progression and invasion and support discovery of more personalized first line treatments for cancer patients.

Indexed as

Antineoplastic AgentsDrug EvaluationModels, BiologicalTissue EngineeringBioreactorsCell Line, TumorCell SurvivalHumansMicrofluidic Analytical TechniquesNeoplasmsTissue ScaffoldsAntineoplastic Agents3D tumor modelsBioreactorsCancer therapeuticsDrug deliveryDrug resistanceHydrogelsMicrofluidic devicesScaffolds

Identifiers

PMID25116894
PMCPMC4171250
OpenAlexW2044722516

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.